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ABSTRACT
For patients with early-stage hepatocellular carcinoma
(HCC), potentially curative treatment options exist, in-
cluding liver transplantation, surgical resection, and
ablation therapy. These treatments are associated with
survival benefits, and outcomes are optimized by iden-
tification of appropriate patients. However, further
studies are needed to definitively confirm optimal treat-
ment approaches for all patients.
Treatment patterns vary in different parts of the
world as a result of geographic differences in the inci-
dence and presentation of the disease. In particular,
because of successful screening programs, a high pro-
portion of tumors that are identified in Japan are ame-
nable to curative treatments, which are appropriate in a
smaller proportion of patients in the west, although
screening is now widely carried out in industrialized
countries. Differences in the applicability of transplan-
tation are also evident between the west and Asia.
Although existing treatments for early-stage HCC are
supported by considerable evidence, there remain sig-
nificant data gaps. For example, further data, ideally
from randomized controlled trials, are needed regard-
ing: the use of neoadjuvant and adjuvant therapy to de-
crease the rate of recurrence after resection or ablation,
further investigation of the role of chemoprevention fol-
lowing resection, and prospective analysis of outcomes
of living donor compared with deceased donor liver
transplantation. The Oncologist 2010;15(suppl 4):34–41
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INTRODUCTION
Hepatocellular carcinoma (HCC) is an increasingly preva-
lent clinical problem worldwide and is the third most com-
mon cause of cancer-related death [1, 2]. The presence of
cirrhosis is a key risk factor [3]. HCC is a complex disease
involving many factors, and HCC staging systems can be
very complicated [4]. The widely used, comprehensive
Barcelona Clinic Liver Cancer staging system takes into ac-
count variables related to tumor stage, liver function, phys-
ical status, and cancer-related symptoms to generate a
treatment algorithm [5].
Treatment is most effective in the early stages of dis-
ease, but diagnosing early-stage HCC is difficult because
the diagnosis of cirrhosis is often not made before the emer-
gence of HCC. Patients at high risk for developing HCC
(e.g., those with cirrhosis, hepatitis B virus, or hepatitis C
virus) should be entered into surveillance programs using
ultrasound and serum -fetoprotein (AFP) [3, 6, 7]. Based
mainly on observational data on tumor-volume doubling
time, a screening interval of 6 months is commonly used by
physicians in the West, in contrast to the Far East, where a
3-month screening interval is generally implemented [8]. In
a recent meta-analysis, a significantly higher sensitivity for
early HCC was observed with a 6-month interval than with
annual surveillance [9]. Because of the high rates of false-
positive and false-negative results in patients with chronic
liver disease, the American Association for the Study of
Liver Diseases (AASLD) does not recommend the use of
AFP alone as a screening method, unless ultrasound is not
available. Information from a recent meta-analysis demon-
strated that AFP provided no additional benefit to ultra-
sound, further supporting this guidance [9]. In contrast,
abdominal ultrasonography combined with measurements
of tumor markers is recommended for HCC screening, and
assessments of AFP, protein induced by vitamin K absence
or antagonist-II, or AFP lectin fraction are routinely per-
formed in Japan [10].
Individuals with abnormal screening results require fur-
ther investigation (e.g., with computed tomography scan-
ning, magnetic resonance imaging, or liver biopsy) to
confirm a diagnosis of HCC. Although surveillance pro-
grams can lead to detection of HCC at early stages when the
tumors are amenable to curative treatment, guidelines are not
always followed and are not always reproducible from large
hospitals to nontertiary hospitals. Further studies are war-
ranted to determine the optimal surveillance methods, which
may also involve evaluation of novel biomarkers in the future.
Treatments for early-stage HCC include hepatectomy,
liver transplantation, and local ablation therapy (Fig. 1) [6,
10–13]. However, there are no large randomized controlled
trials (RCTs) comparing these treatments directly, nor are
there any studies comparing these treatments with best sup-
portive care [6]. In an intent-to-treat analysis in cirrhotic pa-
tients with HCC, early findings suggested similar survival
rates in a comparison of resection with transplantation [14].
However, patient dropouts from waiting lists significantly
impacted the longer-term findings in the transplantation
group, and the authors concluded that resection may pro-
vide a better outcome for properly selected candidates. Fur-
ther research is needed to confirm the optimal strategy
based on the currently available treatments, and careful se-
lection of patients is important in all approaches. Applica-
bility of these treatments varies according to geographic
distribution, with 50%–70% of cases in Japan (where there
is widespread surveillance and a broad application of treat-
ments) being suitable for curative treatment, compared with
25%–40% of cases in Europe and the U.S., and 10% in
Africa [15]. Data from a nationwide survey in Japan indi-
cate that a single early HCC patient has a high chance of
prolonged survival with resection, ablation, or transplanta-
tion [16]. The aim of this article is to review the therapeutic
options and associated outcomes for the management of pa-
tients with early HCC.
OUTCOMES AND TOLERABILITY OF EARLY-STAGE
HCC TREATMENTS
Resection
Patients with early-stage HCC are those most likely to ben-
efit from curative interventions. In a study of patients diag-
nosed with HCC in 1988 –1998 in the Surveillance,
Epidemiology, and End Results database, 417 of the 4,008
patients were candidates for surgical resection. The study
showed that surgery was associated with longer survival in
patients with unifocal, nonmetastatic HCC tumors 5 cm.
In patients receiving surgery, the 5-year overall survival
(OS) rate was 33%, compared with 7% without surgery
[17].
Surgical resection is recommended as treatment for
early HCC in noncirrhotic patients, or in patients with cir-
rhosis who have a single lesion and well-preserved liver
function, normal bilirubin, and no portal hypertension [6,
13]. However, there are data that suggest that portal hyper-
tension may not necessarily be a contraindication for resec-
tion. Patients with the same model for end-stage liver
disease score and extent of hepatectomy had similar out-
comes, whether or not they had portal hypertension [18],
whereas several other studies found that resection can be
performed safely in selected patients even in the presence of
portal hypertension [19, 20]. Patients with multiple tumors
may also be suitable for resection, although tumor multi-
plicity is an independent risk factor for postoperative recur-
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rence, and the OS time is shorter in these patients [20].
However, among patients with both multiple tumors and
better liver function (Child-Pugh class A), an absolute
5-year survival rate of 58% was achieved. Although there is
no limitation on tumor size for resection, the risk for vascu-
lar invasion and dissemination increases with size. The
amount of liver that can be resected depends on the degree
of cirrhosis, the functional liver reserve, and the regenera-
tive capacity of the liver [7]. Strict selection criteria are re-
quired in order to avoid treatment-related complications
such as liver failure. Survival rates of 70% at 5 years have
been achieved in patients with a normal bilirubin concen-
tration and no clinically significant portal hypertension [6].
In Japan, the indocyanine green retention rate, a marker of
hepatic clearance, is commonly used to predict the safe
limit of liver resection and posthepatectomy liver failure
[21]. Preoperative portal vein embolization (PVE) has been
used to evaluate the regenerative abilities of the liver, with
lack of hypertrophy following PVE indicating an inability
of the liver to regenerate, therefore contraindicating major
liver resection [22]. Furthermore, preoperative PVE has
been shown to improve outcomes following major hepatec-
tomy [23]. In patients with very early HCC (carcinoma in
situ) undergoing surgery, the best 5-year survival rate so
far, 93%, was demonstrated [24]. Only 10%–30% of HCC
cases are suitable for “curative” surgical resection at the
time of diagnosis, and recurrent HCC has been reported in
50%–80% of patients 5 years after resection [7]. Key pre-
dictors of recurrence are the presence of microvascular in-
vasion and/or further tumor sites in addition to the primary
lesion. Preoperative transcatheter arterial chemoemboliza-
tion (TACE) has been evaluated but has shown no benefit in
this setting [7]. AASLD and Japanese guidelines conclude
that there is currently no preoperative or postoperative ad-
juvant therapy that can be recommended for improving prog-
nosis after hepatic resection [6, 10]. Further investigation is
required for neoadjuvant and adjuvant therapies that may de-
crease the incidence of recurrence following resection.
Transplantation
Liver transplantation as a treatment for early-stage HCC is
well established in the U.S. and Europe and is associated
CLINICAL
PRESENTATION
SURGICAL ASSESSMENTa,b TREATMENT SURVEILLANCE
UNOS criteria1
5 cm
  diameter or 2–3 tumors
  3 cm each
These patients may be resected
if transplantation not feasible
c
No portal hypertension
Suitable tumor location
Adequate liver reserve
Suitable liver remnant
Imaging every 3–6 mos for 2 yrs,
then annually
AFP, if initially elevated, every
3 mos for 2 yrs, then every 6 mos
Potentially resectable
or transplantable, operable
by performance status or
comorbidity
Liver transplant
Resection or ablation
Figure 1. National Comprehensive Cancer Network guidelines for the treatment of potentially resectable disease.
aDiscussion of surgical treatment with patient and determination of whether patient is amenable to surgery.
bPatients with Child-Pugh class A liver function who fit UNOS criteria and are resectable could be considered for resection or
transplant. There is controversy over which initial strategy is preferable to treat such patients. These patients should be evaluated
by a multidisciplinary team.
cIn highly selected Child-Pugh class B patients with limited resection.
1Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients
with cirrhosis. N Engl J Med 1996;334:693–700.
Abbreviations: AFP, -fetoprotein; UNOS, United Network for Organ Sharing.
From National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers V.
1.2010. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Reproduced with permission from The
NCCN Clinical Practice Guidelines in Oncology™ Hepatobiliary Cancer Guidelines. ©2009 National Comprehensive Cancer
Network, Inc. All rights reserved. These Guidelines and illustrations herein may not be reproduced in any form for any purpose
without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go
online to NCCN.
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with 5-year survival rates of 70% [6], comparable with
those of noncancer liver recipients. In most centers, candi-
dates for transplantation are deemed not resectable. In some
parts of the world, transplantation is not available or has
very limited applicability [6]. The benefits of liver trans-
plantation over resection include removal of the tumor and
the underlying diseased liver and also improvement in por-
tal hypertension. Because of the limited supply of donor
organs, identification of the patients most likely to receive
maximum benefit from a transplant is of utmost impor-
tance. For over a decade, the Milan criteria for HCC (one
lesion 5 cm or two to three lesions 3 cm) have been
widely used for the selection of candidates for liver trans-
plantation. However, there is an ongoing debate on whether
expanded criteria may be adopted, to enable patients with
slightly more advanced HCC to also benefit from liver
transplantation [25]. A 5-year survival rate of 50% was
described in patients selected with such expanded criteria,
but there are currently no clear data to define the new limits
[6]. In addition, expanding the criteria may cause harm to
other patients without cancer who need a transplant, as a re-
sult of fewer donors being available [26]. Because the wait-
ing time for an organ to become available may exceed 12
months in some western countries [27], the dropout rate is
high (up to 50%). Most centers administer adjuvant treat-
ments to prevent tumor progression while patients are on
the waiting list, but these are often chosen based on obser-
vational studies, because robust data from RCTs are not
available. Such bridging therapy before transplantation
may include locoregional therapy such as chemoemboliza-
tion, which has been investigated as a means of downstag-
ing tumors to facilitate liver transplantation [25].
Information from a liver transplant waiting list in the U.S.
showed that HCC patients who received pretransplant ab-
lation treatments had a higher adjusted 3-year post-trans-
plant survival rate than HCC transplant patients who did not
(79% versus 75%; p  .03) [28]. However, in another ret-
rospective cohort study in the U.S., using data from a liver
transplant waiting list, the authors concluded that the ef-
fects of downstaging with neoadjuvant treatment were dif-
ficult to evaluate [29]. It has also been suggested that
resection can be used as a bridging therapy for patients who
have already been enlisted for liver transplant [30]. There is
no definitive evidence confirming that the use of bridging
therapies confers an advantage post-transplantation in
terms of survival and recurrence rates, and no specific rec-
ommendations in relation to bridging strategies (for either
TACE or local ablation therapy) are currently made in the
guidelines [7, 13].
An alternative strategy to increase the pool of available
donor livers is the use of live donor transplantation, which
originated in Asia as a result of the legal and societal con-
straints on cadaveric liver transplantation [27, 31]. The re-
sults appear to be comparable with those from cadaveric
donation [7, 32]; however, this is a complex intervention
and may not have wide applicability.
Ablation
Local ablation therapy, with either radiofrequency ablation
(RFA) or percutaneous ethanol injection (PEI), is com-
monly used to treat small HCCs confined to the liver that
may be unresectable because of the poor general condition
or compromised liver function of the patient. In an RCT
comparing RFA with PEI for early HCC, the 1-year com-
plete response rate was better with RFA than with PEI, al-
though no clear survival advantage was observed in
cirrhotic patients [33]. However, other RCTs [34–36] and a
recent meta-analysis [37] have shown evidence of the su-
periority of RFA over PEI, in terms of longer survival and
better local control of disease, in patients with relatively
preserved liver function and early-stage nonsurgical HCC
(Fig. 2). At 3 years, the pooled analysis showed an OS rate
of 73% in the RFA group, compared with 58% in the PEI
group (p  .001) [37]. However, RFA was associated with
a statistically significant higher rate of adverse events (p 
.001), with 19% of patients (95% confidence interval [CI],
15%–23%) experiencing complications, compared with
10.5% of those treated with PEI (95% CI, 7%–13.5%) [37].
The most frequent complication observed in that study was
severe pain, which was more common with RFA than with
PEI [37]. For studies that reported major complications, the
Study
Lin 2004
Lin 2005
Shiina 2005
Brunello 2008
Overall
1.46 (1.06–2.01)
(95% CI) % weight
Relative risk
1.44 (1.08–1.91)
1.27 (1.08–1.48)
1.04 (0.78–1.38)
1.28 (1.12–1.45)
15.0
18.6
48.2
18.2
100.0
1
Figure 2. Radiofrequency ablation versus percutaneous eth-
anol injection: results of the meta-analysis on overall survival
at 3 years. All based on random-effects meta-analysis.
Abbreviation: CI, confidence interval.
From Bouza C, López-Cuadrado T, Alcázar R et al. Meta-
analysis of percutaneous radiofrequency ablation versus etha-
nol injection in hepatocellular carcinoma. BMC Gastroenterol
2009;9:31, with permission. Originally published by BioMed
Central.
37Ye, Takayama, Geschwind et al.
www.TheOncologist.com
incidence in RFA-treated patients was 4.1% (95% CI,
1.8%– 6.4%), including hemothorax requiring thoracos-
tomy drainage, gastric bleeding, hemoperitoneum, transi-
tory icterus, liver infarction, cutaneous burn, and tumoral
cell seeding, and in PEI-treated patients it was 2.7% (95%
CI, 0.4%–5.1%), including liver abscess, hemoperitoneum,
tumoral cell seeding, and one procedure-related death;
however, this difference was not statistically significant.
This safety profile should be taken into consideration as
part of the overall risk–benefit profile in each individual
case. Further support for the benefit of RFA was provided
by a different meta-analysis, which was more selective in
the studies that it included and showed a higher 3-year OS
rate with RFA than with PEI (odds ratio, 0.47; 95% CI,
0.340–0.670; p  .001) in patients with small HCCs [38].
Local ablation therapy has been compared with resec-
tion in a number of retrospective studies and clinical trials.
Long-term outcomes in 87 patients with single-nodule
HCCs treated with either surgical resection or RFA were
similar [39]. Similarly, 5-year survival rates were compa-
rable in a study of 224 patients with Child-Pugh class A cir-
rhosis treated with either resection (70.4%) or RFA (76.8%)
(p  .561) [40]. A study of 186 patients with small (5 cm)
HCCs found that the choice of treatment should be based on
local factors, such as the availability of resources and ex-
pertise [41]. In contrast to these findings, a study of 149 pa-
tients with HCCs 4 cm comparing resection with
percutaneous ablation found that resection provided better
local control and better long-term survival (median survival
time, 122 months after hepatectomy compared with 66
months after ablation; p  .0123) [42]. A nationwide sur-
vey in Japan generated data on survival following resection
or RFA [16]. In 2000–2003, 1,235 patients with a single
early HCC (2 cm) underwent resection and 1,315 patients
received RFA. Although, with a median follow-up of 37
months, the disease-free survival rate was significantly bet-
ter after resection than after RFA (1 year, 91% versus 84%;
2 years, 70% versus 58%; p  .001), there was no signifi-
cant difference in the OS rate between the two groups (98%
versus 99%; 94% versus 95%; p  .28). However, it is cur-
rently unknown whether the better disease-free survival
seen with resection will translate into longer survival over a
longer time period following therapy. Local ablation ther-
apy was compared with resection in two RCTs in patients
with small HCCs, with comparable survival results [43,
44]. Based on a trial of 180 patients, Chen et al. [43] con-
cluded that RFA was as effective as surgical resection in the
treatment of solitary and small HCCs, with the advantage of
being less invasive. In a smaller study of 76 patients, Huang
et al. [44] reported that PEI appeared to be as safe and ef-
fective as resection. Recent studies have shown that, in
some centers, RFA is regarded as the first-line treatment for
small, operable HCCs (2 cm), with 68.5% of patients sur-
viving at 5 years [45]. Furthermore, in a simulated random-
ized trial comparing hepatic resection with RFA for very
early HCCs (2 cm), the OS times were similar for resec-
tion and RFA followed by resection for cases of initial local
failure, suggesting that RFA could be considered as a pri-
mary treatment for very early HCC [46]. Given these equiv-
ocal results, larger RCTs are needed before there is any
change in the recommended treatment of patients with good
surgical risk and before ablation therapy is confirmed as an
alternative to surgery for potentially resectable HCC.
TACE
Embolization procedures are used in patients with inopera-
ble or unresectable disease. However, the place of TACE
for the treatment of early HCC is not clear, and official
guidelines do not currently recommend it. Caution should
be exercised regarding the use of TACE for early HCC, and
it should be considered only when curative treatment (e.g.,
transplantation, resection, or RFA) is contraindicated.
DIFFERENCES IN THE TREATMENT OF EARLY HCC
AND OUTCOMES BETWEEN POPULATIONS
As described above, well-defined treatment options for
early HCC exist; however, there are inevitable differences
in the treatment received, and hence the outcome achieved,
in different populations worldwide. There are geographic
variations in the incidence and etiology of HCC, and a dif-
ference in tumor size at presentation. Japanese patients
have been shown to present with smaller tumors than pa-
tients in the U.S. and Europe, likely as a result of the more
widespread screening carried out in Japan [47]. This, to-
gether with differences in hepatitis B or C virus status, has
resulted in more limited surgical resections being necessary
in Japan, compared with more extended resections in the
U.S.
In a more recent comparison, analysis of the medical
records of 353 patients subject to surgical resection for
HCC at two referral centers in China and Japan highlighted
differences between populations [48]. As well as demo-
graphic differences in age of incidence, serum examination,
and history of viral infection, differences in outcome were
observed. Patients in Japan were diagnosed earlier, were
subject to more standard treatment, and had better prog-
noses than those in China. However, these results were
based only on HCC at each center and not on HCC detected
in a surveillance program. In addition, the demographic dis-
parities in survival in patients with localized HCC in the
U.S. were investigated in a retrospective cohort study using
data from the Surveillance, Epidemiology, and End Results
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population-based cancer registry [49]. That study found
substantial and significant disparities by race/ethnicity in
the 3-year survival rate, therapy administered, and stage-
specific survival rate for individual therapies. These differ-
ences were not explained by age, date of diagnosis, or
geography, but may have resulted from differences in treat-
ments received by different demographic groups or varia-
tions in treatment response, which may be influenced by
compliance or differences in disease biology. However,
these patients were not identified through a surveillance
program, but were patients diagnosed with HCC, which
may be associated with lead-time bias. In a prospective co-
hort study in Europe, hepatic resection performed under
strict intraoperative ultrasonographic guidance had low
mortality and acceptable morbidity, even in patients with
intermediate and advanced HCC [50].
IMPROVING TREATMENT OPTIONS
There remains a considerable number of unanswered ques-
tions in the recommendations for treatment of early-stage
HCC, many of which require a definitive answer to be pro-
vided through robust data from RCTs. Key areas for con-
sideration include: the use of neoadjuvant or adjuvant
therapy to decrease or delay recurrence after resection or
ablation, chemoprevention after resection or ablation, and
the use of molecular profiling of HCC to provide additional
tools to define those patients most at risk for recurrence fol-
lowing resection. Indeed, a number of clinical trials are on-
going in these areas. Three ongoing phase IV trials are
investigating radiotherapy (ClinicalTrials.gov identifier,
NCT00557024), TACE (ClinicalTrials.gov identifier,
NCT00556803), and lamivudine or entecavir (Clinical-
Trials.gov identifier, NCT00555334) as adjuvant therapies
after RFA, and are due to complete in 2010. Furthermore,
sorafenib (Nexavar; Onyx Pharmaceuticals, Inc., Em-
eryville, CA; Bayer HealthCare Pharmaceuticals, Inc.,
Wayne, NJ; Bayer Schering Pharma AG, Berlin, Germany)
is being investigated as adjuvant treatment in the prevention
of recurrence of HCC following either surgical resection or
local ablation, in the large phase III randomized, double-
blind, placebo-controlled Sorafenib as Adjuvant Treatment
in the Prevention of Recurrence of Hepatocellular Carci-
noma (STORM) trial (ClinicalTrials.gov identifier,
NCT00692770), due to complete in 2011. With regard to
liver transplantation, bridging therapy before transplanta-
tion, including the questions of which treatment to give and
when [7], and prospective analysis of outcomes of living
donor compared with deceased donor transplantation are
areas that warrant further study.
Important considerations in future trials include analy-
sis of the cost-effectiveness of the treatments under inves-
tigation and also the use of genomics- and proteomics-
based technologies [51], in order to add to the body of
information on the biologic behavior and natural history of
HCC, which should help guide the diagnosis and manage-
ment of HCC.
CONCLUSIONS
Early diagnosis remains a key goal in order to improve the
prognosis of HCC patients. Surgical resection and liver
transplantation are usually considered as first-line options
because they offer the possibility of prolonged survival in
patients with early disease and have excellent outcomes in
well-selected patients. Local ablation therapy, using RFA
or PEI, also has a role to play. Further improvements in the
outcome of patients with early HCC may be achieved once
outstanding questions have been answered by prospective
RCTs.
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